GSK re-submits Avodart for prostate cancer risk reduction, while NEJM editorial questions its value
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has re-submitted the supplemental NDA for its drug Avodart (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US FDA, just as a commentary published in the NEJM questions the drug's use for this indication.